Genomewide copy number analysis of Müllerian adenosarcoma identified chromosomal instability in the aggressive subgroup

Modern Pathology

Volumn 29, Issue 9, 2016, Pages 1070-1082

  Lee, Jen Chieh ^a   Lu, Tzu Pin ^b   Changou, Chun A ^c   Liang, Cher Wei ^a   Huang, Hsien Neng ^a   Lauria, Alexandra ^d   Huang, Hsuan Ying ^e   Lin, Chin Yao ^f   Chiang, Ying Cheng ^a,g   Davidson, Ben ^h,i   Lin, Ming Chieh ^a   Kuo, Kuan Ting ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^f CARDINAL TIEN HOSPITAL   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^h OSLO UNIVERSITY HOSPITAL   (Norway)

ⁱ UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HIGH MOBILITY GROUP A2 PROTEIN; PROTEIN MDM2; STAT6 PROTEIN; TRANSCRIPTION FACTOR GLI1; PARAFFIN; TUMOR MARKER;

ADENOSARCOMA; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CHROMOSOMAL INSTABILITY; CHROMOSOME; CHROMOSOME 12Q; CHROMOSOME 16Q; CHROMOSOME 17Q; CHROMOSOME PAINTING; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; CPM GENE; FEMALE; FEMALE GENITAL TRACT CANCER; FLUORESCENCE MICROSCOPY; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULLERIAN ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GENE; YEATS4 GENE; CHEMISTRY; CHROMOTHRIPSIS; GENE DOSAGE; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; MUELLERIAN DUCT; PATHOLOGY; PHENOTYPE; UTERUS CANCER; YOUNG ADULT;

ADENOSARCOMA; ADULT; AGED; BIOMARKERS, TUMOR; CHROMOSOME PAINTING; CHROMOTHRIPSIS; DNA COPY NUMBER VARIATIONS; FEMALE; GENE DOSAGE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULLERIAN DUCTS; PARAFFIN EMBEDDING; PHENOTYPE; UTERINE NEOPLASMS; YOUNG ADULT;

EID: 84976274350     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2016.99     Document Type: Article

References (44)

1. Clement PB, Scully RE. Mullerian adenosarcoma of the uterus. A clinicopathologic analysis of ten cases of a distinctive type of mullerian mixed tumor. Cancer 1974;34:1138-1149.
2. Wells MOE, Palacios J, Prat J. Mixed epithelial and mesenchymal tumours. In: Kurman R, Carcangiu M, Herrington C et al. (eds). WHO Classification of Tumours of Female Reproductive Organs, 4th edn. IARC: Lyon, France, 2014.
3. Major FJ, Blessing JA, Silverberg SG et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 1993;71:1702-1709.
4. Abeler VM, Royne O, Thoresen S et al. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology 2009;54: 355-364.
5. Clement PB. Mullerian adenosarcomas of the uterus with sarcomatous overgrowth. A clinicopathological analysis of 10 cases. Am J Surg Pathol 1989;13:28-38.
6. Kaku T, Silverberg SG, Major FJ et al. Adenosarcoma of the uterus: a Gynecologic Oncology Group clinicopathologic study of 31 cases. Int J Gynecol Pathol 1992;11:75-88.
7. Krivak TC, Seidman JD, McBroom JW et al. Uterine adenosarcoma with sarcomatous overgrowth vs uterine carcinosarcoma: comparison of treatment and survival. Gynecol Oncol 2001;83:89-94.
8. Eichhorn JH, Young RH, Clement PB et al. Mesodermal (mullerian) adenosarcoma of the ovary: a clinicopathologic analysis of 40 cases and a review of the literature. Am J Surg Pathol 2002;26:1243-1258.
9. Clement PB, Scully RE. Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature. Hum Pathol 1990;21: 363-381.
10. Howitt BE, Sholl LM, Dal Cin P et al. Targeted genomic analysis of Mullerian adenosarcoma. J Pathol 2015;235: 37-49.
11. Piscuoglio S, Burke KA, Ng CK et al. Uterine adenosarcomas are mesenchymal neoplasms. J Pathol 2016; 238:381-388.
12. Wang Y, Cottman M, Schiffman JD. Molecular inversion probes: a novel microarray technology and its application in cancer research. Cancer Genet 2012;205:341-355.
13. Kuo KT, Guan B, Feng Y et al. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and highgrade carcinomas. Cancer Res 2009;69:4036-4042.
14. Wolff AC, Hammond ME, Hicks DG et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31: 3997-4013.
15. Rajaram V, Leuthardt EC, Singh PK et al. 9p21 and 13q14 dosages in ependymomas. A clinicopathologic study of 101 cases. Mod Pathol 2004;17:9-14.
16. Changou CA, Chen YR, Xing L et al. Arginine starvation-associated atypical cellular death involves mitochondrial dysfunction, nuclear DNA leakage, and chromatin autophagy. Proc Natl Acad Sci USA 2014;111:14147-14152.
17. Pemble S, Schroeder KR, Spencer SR et al. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 1994;300(Pt 1):271-276.
18. Stephens PJ, Greenman CD, Fu B et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011;144:27-40.
19. Cai H, Kumar N, Bagheri HC et al. Chromothripsis-like patterns are recurring but heterogeneously distributed features in a survey of 22,347 cancer genome screens. BMC Genomics 2014;15:82.
20. Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 2013;13:83-96.
21. Shadfan M, Lopez-Pajares V, Yuan ZM. MDM2 and MDMX: alone and together in regulation of p53. Transl Cancer Res 2012;1:88-89.
22. Momand J, Zambetti GP, Olson DC et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-1245.
23. Matsushime H, Ewen ME, Strom DK et al. Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell 1992;71:323-334.
24. Baker SJ, Reddy EP. CDK4: a key player in the cell cycle, development, and cancer. Genes Cancer 2012;3: 658-669.
25. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002;1602:73-87.
26. Italiano A, Bianchini L, Keslair F et al. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int J Cancer 2008;122: 2233-2241.
27. Erickson-Johnson MR, Seys AR, Roth CW et al. Carboxypeptidase M: a biomarker for the discrimination of well-differentiated liposarcoma from lipoma. Mod Pathol 2009;22:1541-1547.
28. Ray-Coquard I, Blay JY, Italiano et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-ofmechanism study. Lancet Oncol 2012;13:1133-1140.
29. Dickson MA, Tap WD, Keohan ML et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol 2013;31: 2024-2028.
30. Cleynen I, Van de Ven WJ. The HMGA proteins: a myriad of functions (Review). Int J Oncol 2008;32: 289-305.
31. Dal Cin P, Wanschura S, Kazmierczak B et al. Amplification and expression of the HMGIC gene in a benign endometrial polyp. Genes Chromosomes Cancer 1998;22:95-99.
32. Bol S, Wanschura S, Thode B et al. An endometrial polyp with a rearrangement of HMGI-C underlying a complex cytogenetic rearrangement involving chromosomes 2 and 12. Cancer Genet Cytogenet 1996;90: 88-90.
33. Carter SL, Eklund AC, Kohane IS et al. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006;38:1043-1048.
34. Cope L, Wu RC, ShihIe M et al. High level of chromosomal aberration in ovarian cancer genome correlates with poor clinical outcome. Gynecol Oncol 2013;128:500-505.
35. Kramer A, Neben K, Ho AD. Centrosome replication, genomic instability and cancer. Leukemia 2002;16: 767-775.
36. Hernando E, Nahle Z, Juan G et al. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 2004;430: 797-802.
37. Korbel JO, Campbell PJ. Criteria for inference of chromothripsis in cancer genomes. Cell 2013;152: 1226-1236.
38. Rausch T, Jones DT, Zapatka M et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 2012;148:59-71.
39. Hirsch D, Kemmerling R, Davis S et al. Chromothripsis and focal copy number alterations determine poor outcome in malignant melanoma. Cancer Res 2013;73: 1454-1460.
40. Magrangeas F, Avet-Loiseau H, Munshi NC et al. Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients. Blood 2011;118:675-678.
41. Molenaar JJ, Koster J, Zwijnenburg DA et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 2012;483: 589-593.
42. Kim TM, Xi R, Luquette LJ et al. Functional genomic analysis of chromosomal aberrations in a compendium of 8000 cancer genomes. Genome Res 2013;23: 217-227.
43. Kloosterman WP, Koster J, Molenaar JJ. Prevalence and clinical implications of chromothripsis in cancer genomes. Curr Opin Oncol 2014;26:64-72.
44. Matsui A, Ihara T, Suda H et al. Gene amplification: mechanisms and involvement in cancer. Biomol Concepts 2013;4:567-582.